Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report

G Zuglian; D Ripamonti; A Tebaldi; M Rizzi

doi:10.1016/j.mmcr.2019.10.002

Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report

Med Mycol Case Rep. 2019 Oct 3:26:42-43. doi: 10.1016/j.mmcr.2019.10.002. eCollection 2019 Dec.

Authors

G Zuglian¹, D Ripamonti², A Tebaldi², M Rizzi²

Affiliations

¹ University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, 25123, Italy.
² Unit of Infectious Diseases, ASST Papa Giovanni XXIII, Piazza OMS 1, Bergamo, 24129, Italy.

Abstract

Mucormycosis are a group of infections that affect principally immunocompromised host and have a high mortality. Liposomal amphotericin B is the first-line treatment with combined surgical removal of the infectious focus. We report the case of 67-year-old man with idiopathic granulocytic aplasia and a cutaneous lesion caused by Rhizopus arrhizus treated with isavuconazole. Its safety profile and spectrum of activity make it an important therapeutic option.

Keywords: Cutaneous; Immunocompromised; Isavuconazole; Mucormycosis.

Publication types

Case Reports